Articles

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.  

Novel Agents Rouse Responses in Relapsed/Refractory Multiple Myeloma

Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.

CTLA-4/PD-L1 Blockade Boosts Response in HCC

Videos

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.








Dr. Arora on the Evolving Treatment Landscape in Multiple Myeloma 

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Dr. Wong on Recent Developments in AL Amyloidosis

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

UCSF Helen Diller Family Comprehensive Cancer Center

Latest from UCSF Helen Diller Family Comprehensive Cancer Center

New content coming soon, please check back later.